Biogen ( (BIIB) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen shares climbed as investors focused on the company’s plans to close its Apellis acquisition in the second quarter of 2026, a move that would bring in two marketed drugs and bolster its late-stage pipeline. The deal is seen as a strategic push to secure future growth despite near-term profit pressure.
The company reported a solid quarter but trimmed its 2026 revenue outlook and cut adjusted EPS guidance to a range of $14.25 to $15.25, blaming roughly $1.00 per share in acquired R&D charges. While the lower targets weighed on estimates, the market appeared more encouraged by Biogen’s expansion strategy than discouraged by the guidance reset.
More about Biogen
YTD Price Performance: 4.20%
Average Trading Volume: 1,237,543
Technical Sentiment Signal: Hold
Current Market Cap: $26.51B
For further insights into BIIB stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.